After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...